Practical information
Patient Resources
Administration
4 week dosing schedule 1 INITIAL DOSING: 600 mg/day (3 tablets of 200 mg) KISQALI in combination with a NSAI Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for...Twitter Linkedin Facebook Pinterest Google plusMechanism of action
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...
Twitter Linkedin Facebook Pinterest Google plusPatient Information
Revolade
Mélanome
Melanoma - traitement
Traitement du mélanomeThe suspicious skin spot will first be cut away and sent to the laboratory for examination. If this examination shows that it is a melanoma, a second...
Twitter Linkedin Facebook Pinterest Google plusMélanome - Evènements
×